Diabetes mellitus and severe mental illness: Mechanisms and clinical implications

Nature Reviews Endocrinology

Volumn 11, Issue 2, 2015, Pages 79-89

  Holt, Richard I G ^a   Mitchell, Alex J ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ALGORITHM; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE PERSONNEL; HUMAN; LIFESTYLE MODIFICATION; MENTAL DISEASE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; BODY WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; MENTAL DISORDERS;

EID: 84923116290     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.203     Document Type: Review

References (122)

1. Brown, S., Kim, M., Mitchell, C. & Inskip, H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry 196, 116-121 (2010).
2. McGrath, J., Saha, S., Chant, D. & Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30, 67-76 (2008).
3. Saha, S., Chant, D. & McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 64, 1123-1131 (2007).
4. Vancampfort, D. et al. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 12, 240-250 (2013).
5. Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W. & De Hert, M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 39, 295-305 (2013).
6. De Hert, M., Detraux, J., van Winkel, R., Yu, W. & Correll, C. U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8, 114-126 (2012).
7. Allison, D. B. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156, 1686-1696 (1999).
8. American Diabetes Association, American Psychiatric Association; American Association of Clinical Endocrinologists and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601 (2004).
9. Holt, R. I. & Peveler, R. C. Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 49, 1467-1476 (2006).
10. Holt, R. I. & Peveler, R. C. Association between antipsychotic drugs and diabetes. Diabetes Obes. Metab. 8, 125-135 (2006).
11. Holt, R. I., Bushe, C. & Citrome, L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J. Psychopharmacol. 19 (Suppl. 6), 56-65 (2005).
12. Holt, R. I. & Peveler, R. C. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes. Metab. 11, 665-679 (2009).
13. Holt, R. I. Undoing Descartes: integrating diabetes care for those with mental illness. Pract. Diabet. Int. 28, 270-275 (2011).
14. Subramaniam, M., Chong, S. A. & Pek, E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can. J. Psychiatry 48, 345-347 (2003).
15. Taylor, D., Young, C., Mohamed, R., Paton, C. & Walwyn, R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J. Psychopharmacol. 19, 182-186 (2005).
16. Voruganti, L. P. et al. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophr. Res. 96, 215-222 (2007).
17. Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F. & Rosenheck, R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159, 561-566 (2002).
18. McEvoy, J. P. et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80, 19-32 (2005).
19. Cohen, D., Batstra, M. R. & Gispen-de Wied, C. C. Immunological characteristics of diabetes in schizophrenia. Diabetologia 48, 1941-1942 (2005).
20. Spelman, L. M., Walsh, P. I., Sharifi, N., Collins, P. & Thakore, J. H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 24, 481-485 (2007).
21. Hammerman, A. et al. Antipsychotics and diabetes: an age-related association. Ann. Pharmacother. 42, 1316-1322 (2008).
22. Becker, T. & Hux, J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care 34, 398-402 (2011).
23. Jones, L. E., Clarke, W. & Carney, C. P. Receipt of diabetes services by insured adults with and without claims for mental disorders. Med. Care 42, 1167-1175 (2004).
24. Ribe, A. R. et al. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol. Med. 44, 3097-3107 (2014).
25. Fernandez-Egea, E., Miller, B., Bernardo, M., Donner, T. & Kirkpatrick, B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr. Res. 98, 302-306 (2008).
26. Gough, S. C. & O'Donovan, M. C. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J. Psychopharmacol. 19 (Suppl. 6), 47-55 (2005).
27. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427 (2014).
28. Brunetti, A., Chiefari, E. & Foti, D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J. Diabetes 5, 128-140 (2014).
29. Lin, P. I. & Shuldiner, A. R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res. 123, 234-243 (2010).
30. Lovestone, S., Killick, R., Di Forti, M. & Murray, R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 30, 142-149 (2007).
31. Kvajo, M. et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl Acad. Sci. USA 105, 7076-7081 (2008).
32. Liu, Y. et al. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med. Genomics 6 (Suppl. 1), S17 (2013).
33. Jenkinson, C. P. et al. Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians. Int. J. Obes. Relat. Metab. Disord. 24, 1233-1238 (2000).
34. Chiba, M. et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 49, 1145-1149 (2000).
35. Kao, A. C. & Muller, D. J. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics 14, 2067-2083 (2013).
36. Newsome, C. A. et al. Is birth weight related to later glucose and insulin metabolism - A systematic review. Diabet. Med. 20, 339-348 (2003).
37. Thompson, C., Syddall, H., Rodin, I., Osmond, C. & Barker, D. J. Birth weight and the risk of depressive disorder in late life. Br. J. Psychiatry 179, 450-455 (2001).
38. Kajantie, E. & Raikkonen, K. Early life predictors of the physiological stress response later in life. Neurosci. Biobehav. Rev. 35, 23-32 (2010).
39. Colman, I., Ataullahjan, A., Naicker, K. & Van Lieshout, R. J. Birth weight, stress, and symptoms of depression in adolescence: evidence of fetal programming in a national Canadian cohort. Can. J. Psychiatry 57, 422-428 (2012).
40. Vasiliadis, H. M., Gilman, S. E. & Buka, S. L. Fetal growth restriction and the development of major depression. Acta Psychiatr. Scand. 117, 306-312 (2008).
41. Susser, E. et al. Schizophrenia after prenatal famine. Further evidence. Arch. Gen. Psychiatry 53, 25-31 (1996).
42. St Clair, D. et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA 294, 557-562 (2005).
43. McCreadie, R. G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 183, 534-539 (2003).
44. Brown, S., Birtwistle, J., Roe, L. & Thompson, C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29, 697-701 (1999).
45. Chwastiak, L. A., Rosenheck, R. A. & Kazis, L. E. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics 52, 230-236 (2011).
46. Peet, M. Diet, diabetes and schizophrenia: review and hypothesis. Br. J. Psychiatry Suppl. 47, S102-S105 (2004).
47. Mitri, J., Muraru, M. D. & Pittas, A. G. Vitamin D and type 2 diabetes: a systematic review. Eur. J. Clin. Nutr. 65, 1005-1015 (2011).
48. Valipour, G., Saneei, P. & Esmaillzadeh, A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J. Clin. Endocrinol. Metab. 99, 3863-3872 (2014).
49. Seida, J. C. et al. Effect of Vitamin D supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 99, 3551-3560 (2014).
50. de Vet, E., de Ridder, D. T. & de Wit, J. B. Environmental correlates of physical activity and dietary behaviours among young people: a systematic review of reviews. Obes. Rev. 12, e130-e142 (2011).
51. Bhavsar, V., Boydell, J., Murray, R. & Power, P. Identifying aspects of neighbourhood deprivation associated with increased incidence of schizophrenia. Schizophr. Res. 156, 115-121 (2014).
52. Mitchell, A. J. & Dinan, T. G. Schizophrenia: a multisystem disease? J. Psychopharmacol. 24 (Suppl. 4), 5-7 (2010).
53. Fineberg, A. M. & Ellman, L. M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 73, 951-966 (2013).
54. Bradley, A. J. & Dinan, T. G. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J. Psychopharmacol. 24 (Suppl. 4), 91-118 (2010).
55. Venkatasubramanian, G. et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry 164, 1557-1560 (2007).
56. Huber, T. J., Tettenborn, C., Leifke, E. & Emrich, H. M. Sex hormones in psychotic men. Psychoneuroendocrinology 30, 111-114 (2005).
57. Tiihonen, J. et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620-627 (2009).
58. Haddad, P. M. & Dursun, S. M. Neurological complications of psychiatric drugs: clinical features and management. Hum. Psychopharmacol. 23 (Suppl. 1), 15-26 (2008).
59. Haddad, P. M. & Sharma, S. G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21, 911-936 (2007).
60. De Hert, M. et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 101, 295-303 (2008).
61. Jin, H., Meyer, J. M. & Jeste, D. V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry 14, 59-64 (2002).
62. Citrome, L. L. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc.) 40, 445-464 (2004).
63. Smith, M. et al. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 192, 406-411 (2008).
64. Citrome, L. L. et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann. Pharmacother. 41, 1593-1603 (2007).
65. Vancampfort, D. et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 170, 265-274 (2013).
66. Vancampfort, D. et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol. Med. 44, 2017-2028 (2014).
67. Bobo, W. V. et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 70, 1067-1075 (2013).
68. Samaras, K., Correll, C. U., Mitchell, A. J. & De Hert, M. Diabetes risk potentially underestimated in youth and children receiving antipsychotics. JAMA Psychiatry 71, 209-210 (2014).
69. Bushe, C. J. & Leonard, B. E. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J. Clin. Psychiatry 68, 1682-1690 (2007).
70. Rummel-Kluge, C. et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 123, 225-233 (2010).
71. De Hert, M. et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26, 733-759 (2012).
72. Kahn, R. S. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097 (2008).
73. Saddichha, S., Manjunatha, N., Ameen, S. & Akhtar, S. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr. Scand. 117, 342-347 (2008).
74. Graham, K. A., Cho, H., Brownley, K. A. & Harp, J. B. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr. Res. 101, 287-294 (2008).
75. Manu, P. et al. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr. Res. 143, 358-362 (2013).
76. Ngai, Y. F. et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J. Clin. Psychopharmacol. 34, 359-364 (2014).
77. Ardizzone, T. D., Bradley, R. J., Freeman, A. M. III. & Dwyer, D. S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 923, 82-90 (2001).
78. Engl, J. et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol. Psychiatry 10, 1089-1096 (2005).
79. Ballon, J. S., Pajvani, U., Freyberg, Z., Leibel, R. L. & Lieberman, J. A. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol. Metab. 25, 593-600 (2014).
80. Bak, M., Fransen, A., Janssen, J., van Os, J. & Drukker, M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE 9, e94112 (2014).
81. Alvarez-Jimenez, M. et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22, 547-562 (2008).
82. Correll, C. U. et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302, 1765-1773 (2009).
83. Haro, J. M. & Salvador-Carulla, L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 20, 293-301 (2006).
84. Starrenburg, F. C. & Bogers, J. P. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur. Psychiatry 24, 164-170 (2009).
85. Garcia-Tornadu, I. et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 151, 1441-1450 (2010).
86. Alvarez-Jimenez, M. et al. Healthy Active Lives (HeAL). Keeping the body in mind in youth with psychosis. iphYs [online], http://www.iphys.org.au/SHI-13030-HeAL%20update-8-download.pdf (2014).
87. NICE. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk [online], http://guidance.nice.org.uk/PH38 (2012).
88. De Hert, M. et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry 24, 412-424 (2009).
89. NICE. Psychosis and schizophrenia in adults: treatment and management [online], http://www.nice.org.uk/guidance/cg178 (2014).
90. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust. N. Z. J. Psychiatry 39, 1-30 (2005).
91. Poulin, M. J., Cortese, L., Williams, R., Wine, N. & McIntyre, R. S. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can. J. Psychiatry 50, 555-562 (2005).
92. Curtis, J., Newall, H. D. & Samaras, K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv. Psychiatry 6, 347-353 (2012).
93. Pringsheim, T., Panagiotopoulos, C., Davidson, J. & Ho, J. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr. Child. Health 16, 581-589 (2011).
94. Konz, H. W. et al. Screening for metabolic syndrome in older patients with severe mental illness. Am. J. Geriatr. Psychiatry 22, 1116-1120 (2014).
95. van Winkel, R. et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J. Clin. Psychiatry 67, 1493-1500 (2006).
96. Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U. & De Hert, M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med. 42, 125-147 (2012).
97. Morrato, E. H. et al. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32, 1037-1042 (2009).
98. Lord, O., Malone, D. & Mitchell, A. J. Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. Gen. Hosp. Psychiatry 32, 519-543 (2010).
99. Druss, B. G., Rosenheck, R. A., Desai, M. M. & Perlin, J. B. Quality ofpreventive medical care for patients with mental disorders. Med. Care 40, 129-136 (2002).
100. Hardy, S., Hinks, P. & Gray, R. Screening for cardiovascular risk in patients with severe mental illness in primary care: a comparison with patients with diabetes. J. Ment. Health 22, 42-50 (2013).
101. Mitchell, A. J. & Hardy, S. A. Screening for metabolic risk among patients with severe mental illness and diabetes: a national comparison. Psychiatr. Serv. 64, 1060-1063 (2013).
102. Barnes, T. R., Paton, C., Cavanagh, M. R., Hancock, E. & Taylor, D. M. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr. Bull. 33, 1397-1403 (2007).
103. Norris, S. L. et al. Screening adults for type 2 diabetes: a review of the evidence for the, U. S. Preventive Services Task Force. Ann. Intern. Med. 148, 855-868 (2008).
104. Caemmerer, J., Correll, C. U. & Maayan, L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr. Res. 140, 159-168 (2012).
105. McCreadie, R. G. et al. Dietary improvement in people with schizophrenia: randomised controlled trial. Br. J. Psychiatry 187, 346-351 (2005).
106. Menza, M. et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry 65, 471-477 (2004).
107. Chen, C. K., Chen, Y. C. & Huang, Y. S. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry Clin. Neurosci. 63, 17-22 (2009).
108. Holt, R. I., Pendlebury, J., Wildgust, H. J. & Bushe, C. J. Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. J. Clin. Psychiatry 71, 800-805 (2010).
109. Taylor, J. et al. Identifying risk and preventing progression to type 2 diabetes in vulnerable and disadvantaged adults: a pragmatic review. Diabet. Med. 30, 16-25 (2013).
110. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
111. Chiasson, J. L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (2002).
112. Mizuno, Y. et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr. Bull. 40, 1385-1403 (2014).
113. McIntyre, R. S. et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann. Clin. Psychiatry 24, 69-81 (2012).
114. Joffe, G. et al. Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 69, 706-711 (2008).
115. Maayan, L., Vakhrusheva, J. & Correll, C. U. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35, 1520-1530 (2010).
116. NICE Type 2 diabetes: The management of type 2 diabetes [online], http://www.nice.org.uk/guidance/cg87 (2009).
117. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 37 (Suppl. 1), S14-S80 (2014).
118. Larsen, J. R. et al. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open 4, e004227 (2014).
119. Ho, P. M. et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch. Intern. Med. 166, 1836-1841 (2006).
120. Gorczynski, P., Patel, H. & Ganguli, R. Adherence to diabetes medication in individuals with schizophrenia. Clin. Schizophr. Relat. Psychoses http://dx.doi.org/10.3371/CSRP.GOPA.013114.
121. Mitchell, A. J., Malone, D. & Doebbeling, C. C. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br. J. Psychiatry 194, 491-499 (2009).
122. Arnoldy, R., Curtis, J. & Samaras, K. The effects of antipsychotic switching on diabetes in chronic schizophrenia. Diabet. Med. 31, e16-e19 (2014).